Daraxonrasib has shown promising results in patients with previously treated RAS-mutated pancreatic ductal adenocarcinoma (PDAC), according to a Phase 1/2 study published in the New England Journal of Medicine. The drug works by blocking the active “ON” state of RAS proteins, helping stop cancer growth signals. In second-line treatment, patients with RAS G12 mutations achieved

New data showed promising results for daraxonrasib, a new oral drug designed to treat metastatic pancreatic cancer driven by RAS mutations. Researchers described the treatment as a major advance because KRAS mutations, found in more than 90% of pancreatic cancers, were long considered difficult to target with drugs. Daraxonrasib works differently from earlier KRAS inhibitors.

Final results from the Phase 2 PRIMO trial showed that duvelisib (Copiktra) produced strong responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The treatment achieved an overall response rate of 48%, higher than the 25% to 30% typically seen with many single-agent therapies. Complete responses were reported in 33.3% of patients. Results

A recent roundtable discussion highlighted the growing number of treatment options for pancreatic neuroendocrine tumors (pNETs), with therapy choices depending on whether the goal is disease control or tumor shrinkage. Targeted therapies such as everolimus and sunitinib are mainly used to stabilize disease. In the RADIANT-3 trial, everolimus improved progression-free survival to 11 months compared